
All patients in Alpha Tau's glioblastoma trial alive with 100% tumor response and no serious side effects
Alpha Tau Medical announced interim results from its U.S. trial of Alpha DaRT therapy for recurrent glioblastoma, showing all eight treated patients are alive with a median follow-up of 6.9 months and no median survival reached. Among six patients as...





